Interstitial lung disease—From pulmonary perspective to pathogenesis, multidisciplinary approach and treatment
Author:
- 1 May 2023
- journal article
- editorial
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 26 (5) , 823-824
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung diseasePLOS ONE, 2019
- Nintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseNew England Journal of Medicine, 2019
- Why Does an Aging Smoker’s Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?American Journal of Respiratory and Critical Care Medicine, 2019
- Progress in Understanding and Treating Idiopathic Pulmonary FibrosisAnnual Review of Medicine, 2019
- Radiographic Signs and Patterns in Interstitial Lung DiseaseSeminars in Roentgenology, 2019
- Visual HRCT Score to Determine Severity and Prognosis of Idiopathic Pulmonary FibrosisInternational Journal of Respiratory and Pulmonary Medicine, 2018
- Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White PaperThe Lancet Respiratory Medicine, 2018
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011